My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck Kgaa Spns/Adr (OP:MKKGY)

30.23 -0.19 (-0.62%)

Streaming Delayed Price Updated: 1:51 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck Kgaa Spns/Adr

< Previous 1 2 Next >

Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck ↗

June 01, 2021

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA...

Via Benzinga

Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors ↗

June 01, 2021

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT...

Via Benzinga

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share ↗

May 14, 2021

Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The...

Via Benzinga

Topics Initial Public Offering

MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript ↗

May 13, 2021

MKKGY earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer ↗

May 10, 2021

England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as...

Via Benzinga

The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs ↗

April 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...

Via Benzinga

Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio ↗

April 07, 2021

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.